Dec 03, 2019 / 05:30AM GMT
Stig Ogata - Astellas Pharma Inc. - VP of Corporate Communications
Thank you very much for taking your time out of your busy schedules to be here to participate in our teleconference of Astellas Pharma. This morning, the conference was -- was held to announce a merged -- merger of the -- with Audentes. I'll be serving as the moderator today. I am the Vice President and Corporate Communication, Stig Ogata.
But first, allow me to introduce the speakers. Naoki Okamura, Representative Director, Corporate Executive Vice President; next, Head of DDR, Akihiko Iwai. And then Hideki Shima, Head of Pharma Tech; and finally Ulf Tollemar, Primary Focus Lead, Genetic Regulations.
Ulf Tollemar;Vice President - Primary Focus Lead, Genetic Regulations,
Here, my name is Ulf Tollemar. Apology for not being able to speak Japanese.
Unidentified Company Representative -
Now before starting the presentations, allow me to read out the disclaimers. So at the beginning, I'd like to give you some notes. This document contains
Astellas Pharma Inc Acquisition of Audentes Therapeutics Inc Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot